STOCK TITAN
  1. Home
  2. Sec-filings
  3. CGTX
  4. [Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity

Director at Cognition Therapeutics (CGTX) awarded 25,000 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Khattar Jack A. reported acquisition or exercise transactions in this Form 4 filing.

Cognition Therapeutics Inc. director Jack A. Khattar received an equity award of 25,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock upon settlement. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholders’ meeting, contingent on his continued board service. Following this grant, Khattar directly holds 73,500 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Khattar Jack A.
Role null
Type Security Shares Price Value
Grant/Award Common Stock 25,000 $0.00 --
Holdings After Transaction: Common Stock — 73,500 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 25,000 RSUs Equity award to director Jack A. Khattar
Grant price per unit $0.00 per RSU Reported transaction price for RSU award
Shares after transaction 73,500 shares Direct common stock holdings following RSU grant
RSU vesting date June 17, 2027 Earlier of this date or next annual stockholders’ meeting
restricted stock unit ("RSU") financial
"Each share is represented by a restricted stock unit ("RSU")."
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."
vest in full financial
"The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders"
continuous service financial
"subject to the Reporting Person's continuous service as a director as of the applicable vesting date."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Khattar Jack A.
(Last)(First)(Middle)
C/O COGNITION THERAPEUTICS INC
2500 WESTCHESTER AVE.
(Street)
PURCHASE NEW YORK 10577
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
COGNITION THERAPEUTICS INC [ CGTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026A25,000(1)A$0.0073,500D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
/s/ John Brendan Doyle, Attorney-in-Fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Cognition Therapeutics (CGTX) director Jack Khattar report on this Form 4?

Jack A. Khattar reported receiving 25,000 restricted stock units as an equity award. Each RSU converts into one share of Cognition Therapeutics common stock upon settlement, increasing his direct holdings to 73,500 shares after the grant.

How many Cognition Therapeutics RSUs were granted to director Jack Khattar?

He was granted 25,000 restricted stock units. These RSUs represent a contingent right to receive an equal number of Cognition Therapeutics common shares when they settle, subject to their vesting conditions being satisfied over time.

When do Jack Khattar’s 25,000 Cognition Therapeutics RSUs vest?

The 25,000 RSUs vest in full on the earlier of June 17, 2027 or the date of Cognition Therapeutics’ next annual meeting of stockholders, as long as he continues serving as a director through the applicable vesting date.

Did Jack Khattar buy or sell Cognition Therapeutics shares in the market?

No market purchase or sale occurred; the Form 4 shows a grant of 25,000 RSUs at a reported price of $0.00 per unit, reflecting a compensation-related equity award rather than an open-market trading transaction in Cognition Therapeutics stock.

What are Jack Khattar’s Cognition Therapeutics holdings after this RSU grant?

After the grant, Jack Khattar directly holds 73,500 shares of Cognition Therapeutics common stock. This figure includes the effect of the 25,000 RSUs reported in the filing, as shown in the post-transaction ownership column on the Form 4.

What conditions apply to the Cognition Therapeutics RSUs granted to Jack Khattar?

The RSUs vest only if he maintains continuous service as a director through the vesting date. They settle into one share of Cognition Therapeutics common stock per RSU once vested, aligning director compensation with long-term shareholder interests.